Confirmatory Trial Plan For Acrotech’s Folotyn, Beleodaq Needs Rethinking, FDA Panel Says

 
• By Sue Sutter
  
Baseball plate
Acrotech has a responsibility to step up to the plate and confirm the clinical benefits of its suboptimally developed accelerated approval drugs, FDA's Richard Pazdur said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers